High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy

Despite impressive clinical activity in patients with germline BRCA1 and BRCA2 (BRCA1/2) mutant cancers, antitumor responses to poly(ADP-Ribose) polymerase (PARP) inhibitors are variable. We set out to assess the rate of intrapatient radiological differential responses (RDR) to PARP inhibitors, its...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Perez-Lopez, Raquel, Roda, Desam, Jimenez, Begona, Brown, Jessica, Mateo, Joaquin, Carreira, Suzanne, Lopez, Juanita, Banerji, Udai, Molife, L. Rhoda, Koh, Dow-Mu, Kaye, Stan B., de Bono, Johann S., Tunariu, Nina, Yap, Timothy A.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732817/
https://ncbi.nlm.nih.gov/pubmed/29262651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22303
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires